Abstract
Conventional drugs, including disease-modifying drugs, various cytostatic regimens and steroids, are unable to control disease activity in a small group of patients with “malignant” multiple sclerosis (MS). This group of patients could be offered aggressive therapies, such as high-dose immunosuppression followed by haematopoietic stem cell transplant (HSCT). Bone marrow or peripheral blood HSCT has been proposed for the treatment of autoimmune diseases because of its immunosuppressive and immunomodulatory effects, and recapitulation of lymphocyte ontogeny may stabilise or improve the course of MS in some patients.
There have been a few small studies conducted using high-dose immunoablation and HSCT. A recent clinical trial of 85 patients treated by HSCT revealed that more than 60% of patients may benefit from this procedure. Due to the perceived risks associated with HSCT, only patients with malignant MS who no longer benefit from more conventional therapies were enrolled. HSCT is thus a justified and feasible treatment in certain patient groups, although transplant-related mortality must be reduced.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Burt RK, Cohen BA, Lobeck L, Traynor AE, Bredeson C (2003) Autologous hematopoietic stem cell transplantation in multiple sclerosis: Importance of disease stage on outcome. Neurology 60(Suppl 1):A150
Burt RK, Padilla J, Begolka WS, Canto MC, Miller SD (1998) Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 91:2609–2616
Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH (1998) Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92:3505–3514
Burt RK, Traynor A, Ramsey-Goldman R (1997) Hematopoietic stem-cell transplantation for systemic lupus erythematosus. N Engl J Med 337:1777–1778
European Study Group on Interferon β-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Tsompanakou A (1997) Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transpl 20:631–638
Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A, Samijn J, Samign J; Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation) (2002) Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol 249:1088–1097
van Gelder M, van Bekkum DW (1996) Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transpl 18:1029–1034
Goodin DE, North American Study Group on Interferon beta-1b in Secondary Prevention of MS (2000) Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 54(Suppl):2352 (abstract)
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2003) The use of mitoxantrone (Novantrone®) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61:1332–1338
IFN Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology 43:655–661
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294
Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O (1999) Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler 5(1):17–21
Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O, Slavin S (1993) Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 92:765–772
Kozak T, Havrdova E, Pit’ha J, Gregora E, Pytlik R, Maaloufova J, Mareckova H, Kobylka P, Vodvarkova S (2000) High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transpl 25:525–531
McAllister LD, Beatty PG, Rose J (1997) Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transpl 19:395–397
Meloni G, Salvetti M, Cordone I, Mancini M, Mandelli F (1999) Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia. Haematologica 84:665–667
Moore JJ, Snowden J, Pavletic S, Barr W, Burt R (2003) Hematopoietic stem cell transplantation for severe rheumatoid arthritis. Bone Marrow Transpl 32(Suppl 1):S49–S51
Muraro PA, Ingoni RC, Martin R (2003) Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Curr Opin Neurol 16:299–305
Paty D (1999) Results of the 3-years, double-blinded, placebo-controlled study of interferon-beta-1z (Rebif) in secondary progressive MS. Presented at the Ninth Annual Meeting of the European Neurological Society, Milan, Italy, 5–9 June 1999
PRISMS Study Group (1998) Randomised, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504
Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haematopoietic stem-cell transplantation: a phase I study. Lancet 356:701–707
Weinshenker BG, Issa M, Baskerville J (1996) Meta-analysis of the placebotreated groups in clinical trials of progressive MS. Neurology 46:1613–1619
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Havrdova, E. Aggressive multiple sclerosis—is there a role for stem cell transplantation?. J Neurol 252 (Suppl 3), iii34–iii37 (2005). https://doi.org/10.1007/s00415-005-2015-1
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-2015-1